# NIH Reporter #1F31CA306268-01A1

Targeting ALC1 ATPase Activity as a New Synthetic Lethal Strategy for BRCA-Mutant Cancers

**Recipient:** Washington University

**Award Amount:** $50,114.00
**Ceiling:** $50,114.00

**Awarded:** August 20, 2026

**Identifier:** 1F31CA306268-01A1

A National Cancer Institute-funded research fellowship project studying ALC1 ATPase as a potential synthetic-lethal therapeutic target for BRCA-mutant cancers.

### Description

NIH research training project investigating the basis of synthetic lethality between ALC1 ATPase activity and BRCA deficiency, and identifying ALC1 ATPase regions relevant to potential inhibitor development for BRCA-mutant cancers. The project period is August 20, 2026–August 19, 2028.

[View original record](https://reporter.nih.gov/search/J7l2tQ4hHkqRePwGq3m5kA/project-details/11462896)